Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms

References

• Anttila M, Valavaara R, Kivinen S, Mäenpää J. (1990). Pharmacokinetics of toremifene. J Steroid Biochem 36:249–252.
   PubMedGoogle Scholar
• Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P. (1994). Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 47:1883–1895.
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–832.
   PubMed Web of Science ®Google Scholar
• Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Lang T, Nüssler A, Neuhaus P, Zanger UM, Eichelbaum M, Mürdter TE. (2002). The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157–167.
   PubMed Web of Science ®Google Scholar
• Crewe HK, Ellis SW, Lennard MS, Tucker GT. (1997). Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171–178.
   PubMed Web of Science ®Google Scholar
• Dehal SS, Kupfer D. (1997). CYP2D6 catal`es tamoxifen 4-hydroxylation in human liver. Cancer Res 57:3402–3406.
   PubMed Web of Science ®Google Scholar
• Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, Buckley AR. (2002). Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 30:608–612.
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062–1075.
   PubMed Web of Science ®Google Scholar
• FDA. (2006). Drug interaction studies-study design, data analysis, and implications for dosing and labeling. Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER) (Ed.) (pp. 35).
   Google Scholar
• Freedland SJ, Eastham J, Shore N. (2009). Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 12:333–338.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. (2004). Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 44:1273–1281.
   PubMed Web of Science ®Google Scholar
• Kivistö KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. (1998). Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 64:648–654.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL, Alexandre E, Hamilton GA, Viollon-Abadie C, Coon DJ, Jolley S, Richert L. (2005). Isolation and culture of primary human hepatocytes. Methods Mol Biol 290:207–229.
   PubMedGoogle Scholar
• Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.
   PubMed Web of Science ®Google Scholar
• Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P Jr, Koch P, Antonian L, Wagner G, Yu L, Parkinson A. (2003). Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421–431.
   PubMed Web of Science ®Google Scholar
• Mäenpää JU, Ala-Fossi SL. (1997). Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging 11:261–270.
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. (2000). An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031–1037.
   PubMed Web of Science ®Google Scholar
• Meunier V, Bourrié M, Julian B, Marti E, Guillou F, Berger Y, Fabre G. (2000). Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30:589–607.
   PubMed Web of Science ®Google Scholar
• Morello KC, Wurz GT, DeGregorio MW. (2003). Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361–372.
   PubMed Web of Science ®Google Scholar
• Nallani SC, Goodwin B, Buckley AR, Buckley DJ, Desai PB. (2004). Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes. Cancer Chemother Pharmacol 54:219–229.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. (2006). Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab Dispos 34:191–197.
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Drocourt L, Maurel P, Vilarem MJ. (2003). The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta 1619:243–253.
   PubMed Web of Science ®Google Scholar
• Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, Parkinson A. (1996). Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331:145–169.
   PubMed Web of Science ®Google Scholar
• Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448.
   PubMed Web of Science ®Google Scholar
• Rodrigues DA. (2008). Drug–drug interactions (2nd edn. Vol. 179). New York, NY: Informa Healthcare USA, Inc.
   Google Scholar
• Saylor PJ, Keating NL, Smith MR. (2009). Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 24 Suppl 2:S389–S394.
   Web of Science ®Google Scholar
• Segel IH. (1975). Enzyme kinetics: behaviour and analysis of rapid equilibrium and steady-state enzyme systems. New York, NY: John Wiley & Sons, Inc.
   Google Scholar
• Sharifi N, Gulley JL, Dahut WL. (2005). Androgen deprivation therapy for prostate cancer. JAMA 294:238–244.
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240–283.
   PubMed Web of Science ®Google Scholar
• Sipilä H, Näntö V, Kangas L, Anttila M, Halme T. (1988). Binding of toremifene to human serum proteins. Pharmacol Toxicol 63:62–64.
   PubMedGoogle Scholar
• Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. (2010). Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol 184:1316–1321.
   PubMed Web of Science ®Google Scholar
• Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764.
   PubMed Web of Science ®Google Scholar
• Sutton D, Butler AM, Nadin L, Murray M. (1997). Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 282:294–300.
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, Linares GR, DeGregorio MW. (2000). Clinical pharmacokinetics of toremifene. Clin Pharmacokinet 39:327–334.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–toward a consensus. Pharm Res 18:1071–1080.
   PubMedGoogle Scholar
• Tyson C, Green C. (1987). In the isolated hepatocyte: use in toxicology and xenobiotic biotransformation. New York, NY: Academic Press.
   Google Scholar
• Vrzal R, Stejskalova L, Monostory K, Maurel P, Bachleda P, Pavek P, Dvorak Z. (2009). Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact 179:288–296.
   PubMed Web of Science ®Google Scholar
• Wang H, LeCluyse EL. (2003). Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42:1331–1357.
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shimada T. (1998). Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 26:1053–1057.
   PubMed Web of Science ®Google Scholar
• Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD. (2002). Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32:863–878.
   PubMed Web of Science ®Google Scholar